Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Other Non-Current Assets (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Other Non-Current Assets for 15 consecutive years, with $3.9 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Assets fell 16.73% year-over-year to $3.9 million; the TTM value through Mar 2026 reached $3.9 million, down 16.73%, while the annual FY2025 figure was $3.9 million, 16.79% down from the prior year.
  • Other Non-Current Assets hit $3.9 million in Q1 2026 for Agios Pharmaceuticals, roughly flat from $3.9 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $4.7 million in Q4 2024 and bottomed at $2.9 million in Q1 2022.
  • Average Other Non-Current Assets over 5 years is $4.0 million, with a median of $4.0 million recorded in 2022.
  • Year-over-year, Other Non-Current Assets skyrocketed 36.41% in 2022 and then dropped 16.79% in 2025.
  • Agios Pharmaceuticals' Other Non-Current Assets stood at $4.0 million in 2022, then grew by 2.55% to $4.1 million in 2023, then rose by 16.44% to $4.7 million in 2024, then decreased by 16.79% to $3.9 million in 2025, then changed by 0.0% to $3.9 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $3.9 million, $3.9 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.